Tralokinumab Market Drug Insight and Market Forecast - 2032

“Tralokinumab Market Drug Insight and Market Forecast - 2032” report provides comprehensive insights about tralokinumab for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the tralokinumab for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the tralokinumab for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the tralokinumab market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

Tralokinumab (Adbry/ Adtralza) is a fully human monoclonal antibody that specifically neutralizes the IL-13 cytokine, a key driver of the underlying inflammation in AD, and inhibits its interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL13Rα2). IL-13 is a naturally occurring cytokine of the Type 2 immune response. Tralokinumab-ldrm inhibits the bioactivity of IL-13 by blocking IL-13 interaction with IL-13Rα1/IL-4Rα receptor complex. Tralokinumab-ldrm inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE (FDA, 2021). Tralokinumab is produced in mouse myeloma cells by recombinant DNA technology. Tralokinumab can be used with or without topical corticosteroids. The use of topical corticosteroids, when appropriate, may provide an additional effect to the overall efficacy of tralokinumab. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas. The drug was essentially developed by AstraZeneca's MedImmune biologics division, and LEO paid USD 115 million for rights in dermatology indications in 2016.

Adtralza has been approved by the European Commission for adults with moderate-to-severe AD in Europe and by the Medicines and Healthcare products Regulatory Agency in Great Britain, in June 2021. Additional regulatory filings are underway with other health authorities worldwide.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the tralokinumab description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.
• Elaborated details on tralokinumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the tralokinumab research and development activities in atopic dermatitis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around tralokinumab.
• The report contains forecasted sales of for atopic dermatitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.
• The report also features the SWOT analysis with analyst views for tralokinumab in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Tralokinumab Analytical Perspective

In-depth Tralokinumab Market Assessment

This report provides a detailed market assessment of tralokinumab for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

Tralokinumab Clinical Assessment

The report provides the clinical trials information of tralokinumab for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence tralokinumab dominance.
• Other emerging products for atopic dermatitis are expected to give tough market competition to tralokinumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of tralokinumab in atopic dermatitis.
• This in-depth analysis of the forecasted sales data of tralokinumab from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the tralokinumab in atopic dermatitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of tralokinumab?
• What is the clinical trial status of the study related to tralokinumab in atopic dermatitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the tralokinumab development?
• What are the key designations that have been granted to tralokinumab for atopic dermatitis?
• What is the forecasted market scenario of tralokinumab for atopic dermatitis?
• What are the forecasted sales of tralokinumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to tralokinumab for atopic dermatitis?
• Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?

This product will be delivered within 2 business days.